Clinical trial
A Phase I/II, Open-Label, Dose-Escalation, Pilot Study to Evaluate Safety and Preliminary Efficacy of Visilizumab as Primary Therapy for Acute Graft-Versus-Host Disease After Hematopoietic Cell Transplantation
NCT00032292 is registered in ClinicalTrials.gov with Facet Biotech as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II, Open-Label, Dose-Escalation, Pilot Study to Evaluate Safety and Preliminary Efficacy of Visilizumab as Primary Therapy for Acute Graft-Versus-Host Disease After Hematopoietic Cell Transplantation
- Lead sponsor
- Facet Biotech
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- March 31, 2002
- Completion date
- August 31, 2006
- Enrollment
- 34
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.